Follow-up of patients with severe eosinophilic asthma receiving mepolizumab for one year in specialized asthma clinics in Greece

Introduction: Μepolizumab is a monoclonal antibody against IL-5 for the treatment of severe eosinophilic asthma. The aim of the current study was to present a predesigned interim analysis of the data of patients who have completed one year of therapy with mepolizumab. Material and Method: This study is a prospective multi-centre, non-interventional 2 -year observational study and aims to describe the clinical benefit and safety profile of mepolizumab in patients with severe eosinophilic asthma. Results: Compared to the year preceding the initiation of treatment, the annual rate of exacerbations decreased significantly, from 4.3±2.3 to 1.3±1.8; p Conclusions: We have shown that in patients with severe eosinophilic asthma, one year of treatment with mepolizumab was safe, resulted in significant reduction of the annual exacerbation rate, reduction (or even discontinuation) of the needed dose of oral corticosteroids, and improvements of asthma control and lung function.